Specialist investor incubating and accelerating development of innovative biotech companies
ITH is a biotech investment company located at Karolinska Institutet and the Karolinska University Hospital dedicated to innovating the next generation of personalized therapeutics and diagnostics for patients with immune related diseases.
The company’s holding structure is organized to facilitate flexible and independent development of multiple innovations in parallel while maintaining synergies throughout the R&D portfolio with shared common services and expertise.
Investors & Grants





Team

Hans Glise
Chairman
Hans Glise
Chairman
Hans Glise MD, PhD has a professorship in surgery, vast experience of clinical research both from the clinical side and as Head of Clinical research in several Therapy Areas in Astra Zeneca, Novo Nordisk and UCB. Dr Glise also was the drivning force behind the creation of SCUR, a clinical research group of 30 clinics in medicine and Surgery in Sweden, Norway and Finland.

Ahsan Amjad
Managing Director & CEO
Ahsan Amjad
Managing Director & CEO
Ahsan is a health-tech entrepreneur and investor specialising in digital health and immunotherapy. In addition to his role at ITH, Ahsan is co-Founder/Chairman at Accelerated Innovation and Managing Director at TLA, and has been an investor and Board member at several digital health companies such as Geras Solutions, KRY, HerCare, ImagineCare, and ABC Labs.

Ola Winqvist
Chief Scientific Officer
Ola Winqvist
Chief Scientific Officer
Ola is a Senior Consultant in Clinical Immunology at Karolinska University Hospital and co-founder of several biotech companies based on his inventions. Previously, Ola was a Professor of Cellular Immunotherapy and Head of Translational Immunology at the Karolinska Institutet.
Contact
ITH, Immune Therapy Holdings AB
Nanna Svartz Väg 2
171 65 Solna
Sweden
martin.hyllienmark@ithgroup.se
